Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05673304
Recruiting Not applicable

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

NCT05673304 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Not applicable
Started
2023-05-24
Last updated
2024-12-18

Condition(s) studied

Breast CancerRadiotherapy

Investigational drug(s) / intervention(s)

SBRT anticipated boost

SBRT anticipated boost: 24 Gy in 3 fractions to the tumour

Study summary

IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC).

As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Luminal B-like BC, cT1-2 * Indication for neoadjuvant chemotherapy Exclusion Criteria: * Pregnancy * Breast feeding * Patient not available for follow up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy Recruiting

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy

Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency Recruiting
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments Recruiting
Transcriptomics as an Aid in the Histological Diagnosis of Acute Rejection After Liver Transplantation Recruiting
Predictive Value of SFlt-1/PlGF Ratio for the Diagnosis of Cardiovascular Disorders in the Puerperium: Pilot Study Active, not recruiting
Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients Recruiting

Other trials for the same condition

Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes. Recruiting
Extracellular Vesicles in Breast Cancer Patientsin Undergone Neoadjuvant Chemotherapy Recruiting
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women Recruiting
Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer Recruiting
TRACE4BUS for BI-RADS Classification Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05673304 on ClinicalTrials.gov ↗ ← All trials in Italy